CLINICAL TRIALS PROFILE FOR MUPIROCIN CALCIUM
✉ Email this page to a colleague
All Clinical Trials for mupirocin calcium
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01827358 ↗ | Safety and Efficacy of Mupirocin in Eradicating Colonization With S. Aureus in Critically Ill Infants | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | 2014-04-30 | The objective of this trial is 1) to evaluate the safety and clinical acceptability of a 5-day course of mupirocin applied every 8 hours (± 2 hours) to the nares, umbilical and perianal areas of infants residing in the ICU. 2) to examine the efficacy of mupirocin in eradicating SA colonization of infants in the ICU, defined as the absence of SA in cultures of the nares, umbilical, and perianal areas on day 8 (± 2) (primary decolonization) 3) to examine the efficacy of mupirocin in achieving persistent eradication of SA colonization among infants residing in the ICU,defined as the absence of SA in cultures of the nares, umbilical, and perianal areas. Duration is 36 months. Enrolled infants will continue to receive medical care as they otherwise would if they were not enrolled in the trial. The study will be powered with a primary endpoint with 126 participants. Enrollment may continue to 500 participants to power secondary and exploratory endpoints and assist design subsequent studies. |
| NCT01876550 ↗ | A Study to Evaluate the Safety and Bioequivalence of Mupirocin Calcium Cream, 2% and Bactroban® Cream and Compare Both to a Vehicle in Treatment of Secondarily Infected Traumatic Skin Lesions. | Completed | Taro Pharmaceuticals USA | Phase 1 | 2013-02-01 | The primary objective of this study is to determine the comparability of the safety and efficacy of Mupirocin Calcium Cream, 2% and Bactroban® Cream in subjects with secondarily infected traumatic skin lesions. It will also be determined whether the efficacy of each of the active treatments is superior to that of the vehicle cream (placebo). |
| NCT04155203 ↗ | To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Secondarily Infected Traumatic Skin Lesions | Completed | Perrigo Company | Phase 3 | 2019-10-15 | To compare the safety and efficacy of Perrigo's product to an FDA approved product, and to Compare Both Active Treatments to a Vehicle Control in the Treatment of Secondarily Infected Traumatic Skin Lesions |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for mupirocin calcium
Condition Name
Clinical Trial Locations for mupirocin calcium
Trials by Country
Clinical Trial Progress for mupirocin calcium
Clinical Trial Phase
Clinical Trial Sponsors for mupirocin calcium
Sponsor Name
